AJP - GI AJP: Cell Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol 274: G29-G34, 1998;
0193-1857/98 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Masuda, M.
Right arrow Articles by Miyasaka, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Masuda, M.
Right arrow Articles by Miyasaka, K.
Vol. 274, Issue 1, G29-G34, January 1998

Inhibitory effect of central dopamine on basal pancreatic secretion in conscious rats

Masao Masuda, Setsuko Kanai, and Kyoko Miyasaka

Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173, Japan

We examined the role and the peripheral mechanism of action of central dopamine on basal pancreatic exocrine secretion in conscious rats. Rats were fitted with bile and pancreatic catheters to collect bile and pancreatic juice separately and also with a left lateral brain ventricle and external jugular vein catheters. After 90-min basal collection, the D1- and D2-receptor antagonists (Sch-23390 and eticlopride, respectively) and dopamine were administered into the lateral brain ventricle. Sch-23390 (30, 100, and 300 nmol/rat), but not eticlopride (300 nmol/rat), stimulated pancreatic fluid and protein secretion. Dopamine (30, 100, and 300 nmol/rat) inhibited pancreatic secretion dose dependently. Pretreatment with Sch-23390 prevented the inhibitory effect of dopamine. Intravenously injected Sch-23390 or dopamine had no effect on pancreatic secretion. The inhibitory effect of dopamine was blocked by bretylium, an inhibitor of norepinephrine release, and phentolamine, an alpha -blocker, but not by vagotomy. The beta -antagonist propranolol alone significantly inhibited basal pancreatic secretion, and dopamine did not modify the inhibitory effect of propranolol. The proton pump inhibitor omeprazole partially but not completely reduced the inhibition by dopamine. These results suggest that central dopamine inhibits pancreatic exocrine secretion via D1-like receptors and that the inhibitory effect is mediated via sympathetic nerves, especially alpha -adrenoceptors.

intracerebroventricular administration; pancreatic exocrine secretion; D1-like receptor; sympathetic nerve; alpha -adrenoceptor


This article has been cited by other articles:


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. Takano, S. Kanai, H. Hosoya, M. Ohta, H. Uematsu, and K. Miyasaka
Orexin-A does not stimulate food intake in old rats
Am J Physiol Gastrointest Liver Physiol, December 1, 2004; 287(6): G1182 - G1187.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. L. Berfield, L. C. Wang, and M. E. A. Reith
Which Form of Dopamine Is the Substrate for the Human Dopamine Transporter: the Cationic or the Uncharged Species?
J. Biol. Chem., February 19, 1999; 274(8): 4876 - 4882.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online